Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 146, Issue 6, 2009, Pages 660-664

  Shanafelt, Tait D ^a   Byrd, John C ^b   LaPlant, Betsy ^a   Zent, Clive S ^a   Call, Tim ^a   Secreto, Charla ^a   Grever, Michael R ^b   Lin, Thomas S ^b   Kay, Neil E ^a  

^a Mayo Clinic   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Chronic lymphocytic leukaemia; Prognostic factors.; Therapy; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTOR; MONOCLONAL ANTIBODY; PENTOSTATIN; RITUXIMAB; THROMBOSPONDIN 1; VASCULOTROPIN;

ARTICLE; BLOOD; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTORS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PENTOSTATIN; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77449133325     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07811.x     Document Type: Article

References (15)

1. Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A. & Larson, R.A. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, 6-14.
2. Eichhorst, B.F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., Siehl, S., Jager, U., Bergmann, M., Stilgenbauer, S., Schweighofer, C., Wendtner, C.M., Dohner, H., Brittinger, G., Emmerich, B. & Hallek, M. (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 107, 885-891.
3. Gora-Tybor, J., Blonski, J.Z. & Robak, T. (2002) Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma, 49, 145-148.
4. Hallek, M. (2008) Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression- free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood, 112, Abstract 325.
5. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R. & Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine, 350, 2335-2342.
6. Kay, N.E., Bone, N.D., Tschumper, R.C., Howell, K., Geyer, S., Dewald, G., Hanson, C. & Jelinek, D. (2002) B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia, 16, 911-919.
7. Kay, N.E., Geyer, S.M., Call, T.G., Shanafelt, T.D., Zent, C.S., Jelinek, D.F., Tschumper, R., Bone, N.D., Dewald, G.W., Lin, T.S., Heerema, N.A., Smith, L., Grever, M.R. & Byrd, J.C. (2007a) Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood, 109, 405-411.
8. Kay, N.E., Shanafelt, T.D., Strege, A.K., Lee, Y.K., Bone, N.D. & Raza, A. (2007b) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leukemia Research, 31, 899-906.
9. Keating, M., O'brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M., Lynn, A. & Kantarjian, H. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4079-4088.
10. Molica, S., Montillo, M., Ribatti, D., Mirabelli, R., Tedeschi, A., Ricci, F., Veronese, S., Vacca, A. & Morra, E. (2007) Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia. Haematologica, 92, 1367-1374.
11. Ribatti, D., Nico, B., Crivellato, E., Roccaro, A.M. & Vacca, A. (2007) The history of the angiogenic switch concept. Leukemia, 21, 44-52.
12. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R. & Johnson, D.H. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Journal of Medicine, 355, 2542-2550.
13. Shanafelt, T.D. & Kay, N.E. (2006) The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Seminars in Oncology, 33, 174-185.
14. Smolej, L., Andrys, C., Krejsek, J., Belada, D.Z., Zak, P., Siroky, O. & Maly, J. (2007) [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment]. Vnitrni Lekarstvi, 53, 1171-1176.
15. Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D.A., Cortes, J., Lerner, S. & Keating, M.J. (2008) Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 112, 975-980.